Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus
Author(s) -
Tim R. Cressey,
Linda Harrison,
Jullapong Achalapong,
Prateep Kanjanavikai,
Orada Patamasingh Na Ayudhaya,
Prateung Liampongsabuddhi,
Thitiporn Siriwachirachai,
Chaiwat Putiyanun,
Pornnapa Suriyachai,
Camlin Tierney,
Nicolas Salvadori,
Dujrudee Chinwong,
Luc Decker,
Yardpiroon Tawon,
Trudy V. Murphy,
Nicole NgoGiangHuong,
George K. Siberry,
Gonzague Jourdain
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01686-18
Subject(s) - tenofovir , pregnancy , medicine , hepatitis b virus , transmission (telecommunications) , obstetrics , virology , hepatitis b , randomized controlled trial , virus , human immunodeficiency virus (hiv) , biology , genetics , electrical engineering , engineering
We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom